Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 799 results for "clopidogrel"

Human medicines European public assessment report (EPAR): Cl...

This is a summary of the European public assessment report (EPAR) for Clopidogrel Apotex. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing ... European Medicines Agency, 19 hours ago
Clopidogrel: A multifaceted affair Journal of Clinical Pharmacology, 4 days ago

4 images for clopidogrel

Cath Lab Digest, 1 week ago
Pharma Letter, 2 weeks ago
Pharma Letter, 2 weeks ago
Securities Technology Monitor, 2 weeks ago

Prasugrel Plus Bivalirudin vs Clopidogrel Plus Heparin STEMI

Task Force on the management of STseamiotESoC, Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, ...
 General Medicine eJournal1 week ago
Securities Technology Monitor

BRILINTA Preferred Over Clopidogrel in 2014 AHA/ACC Guideline for the Management of Non-ST-Elevation Acute Coronary Syndromes

AHA/ACC Gives Class IIa Recommendation for Use of BRILINTA ® Tablets Over Clopidogrel in NSTE-ACS Patients with Early Invasive or Ischemia-guided Strategy or Receiving a Coronary Stent. WILMINGTON, Del.---- AstraZeneca today confirmed that the ...
 CNBC2 weeks ago AstraZeneca PLC Release: BRILINTA Preferred Over Clopidogrel In 2014 American Heart Association/American College of Cardiology Guideline For The Management Of Non???ST-Elevation Acute Coronary Syndromes  BioSpace2 weeks ago Vorapaxar with or without clopidogrel after nonST-segment elevation acute coronary syndromes: Results from the TRACER trial - Accepted Manuscript  American Heart Journal1 month ago Impact of Diabetes Mellitus and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients With Stable Coronary Artery Disease Undergoing Drug-Eluting Stent Placement - Accepted Manuscript  American Heart Journal1 month ago
[x]  

ISAR-TRIPLE: Six-Week vs Six-Month Clopidogrel in DES and AF

My name is Nikolaus Sarafoff, from Munich, and I want to present the results of the ISAR-TRIPLE trial, which I had the honor to present on behalf of all coauthors at the TCT convention in Washington. Patients with an indication for oral ...
 Medscape3 weeks ago ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following___  TCTMD.com1 month ago

TRANSLATE-ACS: No MACE Benefit With Prasugrel in ACS

WASHINGTON, DC — A real-world comparison of clopidogrel vs prasugrel (Effient, Lilly/Daiichi-Sankyo) in nearly 12 000 acute coronary syndrome (ACS) patients undergoing PCI revealed no significant differences in the rate of major adverse ...
 American Journal of Public Health1 month ago TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing___  TCTMD.com1 month ago

Ticagrelor vs Clopidogrel in Non-ST-Elevation ACS

Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S ...
 General Medicine eJournal1 month ago

Advancement of Ascendia Pharmaceutical's Nano-Emulsion Technology Platform with Its Lead Development Program ASD-002

There is a significant unmet medical need for a parenteral clopidogrel dosage form for the treatment of Acute Coronary Syndrome under life-threatening situations, said Jingjun Jim Huang, Ph.D ., CEO of Ascendia. With our ...
 Morningstar.com1 month ago Ascendia Applies Nano-Emulsion Technology to Injectable Blood Thinner Medicine  Azonano1 month ago Advancement of Ascendia's nano-emulsion technology platform with Its lead development program ASD-002  Pharmaceutical Business Review1 month ago
[x]  

McCormack Pharma announces a breakthrough discovery in the mechanism of clopidogrel resistance

Endogenous failsafe mechanism bypasses the effects of anti-platelet drug Tuesday 21st October 2014 A landmark discovery by McCormack Pharma (aka McCormack Drug Research) provides a new insight into why some patient subgroups are at increased risk of ...
 PharmiWeb1 day ago

Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease

by Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in ...
 Plosone.org6 days ago

GW25-e5249 The drug interaction of clopidogrel carboxylic acid and atorvastatin: A study based on bioinformatic analysis

Note: Since your browser does not support Javascript, you must press the Continue button once
 Journal of the American College of Cardiology1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less